Robert B. Bazemore - 18 Aug 2026 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Reporting relationship: Director
Issuer ticker: AKTX
Reported as of: 18 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Oct 2026, 17:20:11 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Abizer Gaslightwala, as Attorney-in-Fact

Key filing fact

Robert B. Bazemore filed Form 4 for Akari Therapeutics Plc (AKTX) on 16 Oct 2026.

Key facts

This page summarizes Robert B. Bazemore's Form 4 filing for Akari Therapeutics Plc (AKTX).
8 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 16 Oct 2026, 17:20.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001620152 Primary reporting owner

Bazemore Robert B

Relationship: Director
Address: C/O AKARI THERAPEUTICS PLC, 401 EAST JACKSON STREET, SUITE 3300, TAMPA
Signature: /s/ Abizer Gaslightwala, as Attorney-in-Fact
Signature date: 16 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKTX transaction

American Depositary Shares representing Ordinary Shares

Award

Transaction value
Shares: +13,100
Change %: +1174%
Price: $7.90^*
Shares after: 14,216
Date: 18 Aug 2026
Ownership: Direct
Footnotes: F1, F3

AKTX transaction

American Depositary Shares representing Ordinary Shares

Award

Transaction value
Shares: +4,677
Change %: +33%
Price: $7.90^*
Shares after: 18,893
Date: 05 Oct 2026
Ownership: Direct
Footnotes: F2, F3

AKTX transaction

American Depositary Shares representing Ordinary Shares

Options Exercise

Transaction value
Shares: +773
Change %: +4.1%
Price: $0.000400^*
Shares after: 19,666
Date: 14 Oct 2026
Ownership: Direct

AKTX transaction

American Depositary Shares representing Ordinary Shares

Options Exercise

Transaction value
Shares: +3,093
Change %: +16%
Price: $0.000400^*
Shares after: 22,759
Date: 14 Oct 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +45,000
Change %
Price: $0.000000^*
Shares after: 45,000
Date: 18 Aug 2026
Ownership: Direct
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 45,000
Exercise price: $7.90
Footnotes: F4

AKTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +15,000
Change %
Price: $0.000000^*
Shares after: 15,000
Date: 18 Aug 2026
Ownership: Direct
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 15,000
Exercise price: $7.90
Footnotes: F5

AKTX transaction Derivative

Pre-Funded Warrant to Purchase ADSs

Options Exercise

Transaction value
Shares: -773
Change %: -100%
Price: $16.16^*
Shares after: 0
Date: 14 Oct 2026
Ownership: Direct
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 773
Exercise price: $0.000400
Footnotes: F6, F7, F8, F10

AKTX transaction Derivative

Pre-Funded Warrant to Purchase ADSs

Options Exercise

Transaction value
Shares: -3,093
Change %: -100%
Price: $16.16^*
Shares after: 0
Date: 14 Oct 2026
Ownership: Direct
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 3,093
Exercise price: $0.000400
Footnotes: F6, F7, F9, F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

These American Depositary Shares ("ADSs") represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of Directors of the Issuer on August 18, 2026, and is subject to forfeiture if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan ("Shareholder Approval") is not obtained. The RSUs will vest in full on the date of Shareholder Approval.

Footnote F2

These ADSs represent RSUs, with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of Directors of the Issuer on October 5 2026, and is subject to forfeiture if Shareholder Approval is not obtained. The RSUs will vest in full on the date of Shareholder Approval.

Footnote F3

This award of RSUs was granted in lieu of accrued but unpaid cash retainers payable to non-execute directors in accordance with the Company's remuneration policy.

Footnote F4

On August 18, 2026, the Reporting Person was granted an option to purchase 45,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. The option will vest with respect to 33% of the grant on the date of Shareholder Approval plus 2.91% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the two-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Footnote F5

On August 18, 2026, the Reporting Person was granted an option to purchase 15,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. Beginning on the date of Shareholder Approval, this option will vest with respect to 8.33% of the grant on the date of Shareholder Approval plus 8.33% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the one-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Footnote F6

The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.

Footnote F7

The pre-funded warrants remain exercisable until fully exercised.

Footnote F8

On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 773 ADSs.

Footnote F9

On December 16, 2025, the Reporting Person and the Issuer entered into a securities purchase agreement, pursuant to which the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Private Placement Pre-Funded Warrants") to purchase up to 3,093 ADSs, at a purchase price of $16.16 per Private Placement Pre-Funded Warrant, and (ii) warrants to purchase up to 3,093 ADSs.

Footnote F10

The combined purchase price per one pre-funded warrant and accompanying warrant was $16.16.